This phase II trial is studying the side effects and how well proton beam radiation therapy works in treating patients with grade I, grade II, or grade III meningioma or hemangiopericytoma. Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells. Specialized radiation therapy, such as proton beam radiation therapy, that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue in patients with brain tumors.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT01117844.
PRIMARY OBJECTIVES:
I. The primary objectives of this study are feasibility and safety.
SECONDARY OBJECTIVES:
I. To assess acute side effects from irradiation using proton beam therapy in place of conventional photon beam therapy for the treatment of meningiomas.
II. To assess quality of life outcomes, with a focus on the rate of severe fatigue at 6 and 12 months from end of treatment.
III. To assess late complications from irradiation using proton beam therapy in place of conventional photon beam therapy for the treatment of meningiomas.
IV. To compare the dose distribution to tumor and surrounding normal structures using dose volume histograms (DVH's) generated from the proton plan used to treat the patient and the photon plan generated for comparison purposes.
V. To determine 1-yr local control and progression-free and overall survival using proton radiotherapy.
OUTLINE:
Patients undergo proton beam radiotherapy over 6-8 weeks in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 3 months for 1 year, every 6 months for 2 years, and then annually for 2 years.
Lead OrganizationUniversity of Pennsylvania/Abramson Cancer Center
Principal InvestigatorRobert Allan Lustig
